Repligen Co. (NASDAQ:RGEN) Receives Consensus Recommendation of Moderate Buy from Analysts

Repligen Co. (NASDAQ:RGEN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price target […]

Related Keywords

United States ,America ,James Bylund ,Stifel Nicolaus ,Anthony Hunt ,Asia Pacific ,Nasdaq ,Keycorp ,Invesco Ltd ,Repligen Corporation ,Vanguard Group Inc ,Repligen Company Profile ,Pricet Rowe Associates Inc ,Repligen Co ,Artisan Partners Limited Partnership ,Get Free Report ,Marketbeat Ratings ,Street Corp ,Partners Limited Partnership ,Get Free ,North America ,Repligen Daily ,Repligen ,Nasdaq Rgen ,Rgen ,Medical ,75991610 ,Ratings ,Consensus ,